BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
BioNTech is expanding its global footprint with the purchase of Kite Pharma's neoantigen TCR R&D program and manufacturing plant • Source: Shutterstock
